论文部分内容阅读
目的旨在分析吉非替尼治疗晚期肺腺癌疗效的预测因素。方法对2005年12月至2007年12月期间在广州医学院第一附属医院接受吉非替尼单药治疗且进行了EGFR基因突变检测的29例局部晚期或转移性肺腺癌患者的临床、病理特征与吉非替尼治疗疗效的相关情况进行了回顾性分析。结果 29例患者客观缓解率为51.7%,疾病控制率为82.8%,中位疾病进展时间3.2个月;EGFR基因突变阳性患者的客观缓解率、疾病控制率和疾病无进展时间均显著优于EGFR基因野生型患者;不吸烟患者的客观缓解率和疾病无进展时间均显著优于吸烟者;性别、临床分期状况与吉非替尼治疗疗效无明显相关。结论吉非替尼治疗晚期复治性肺腺癌疗效显著,不良反应轻微;EGFR基因突变阳性和不吸烟是预测吉非替尼治疗肺腺癌疗效的有益标志。
The purpose is to analyze the predictors of efficacy of gefitinib in the treatment of advanced lung adenocarcinoma. Methods From December 2005 to December 2007 in the First Affiliated Hospital of Guangzhou Medical College received gefitinib monotherapy and EGFR gene mutation detected in 29 patients with locally advanced or metastatic lung adenocarcinoma of the clinical, The pathological features and gefitinib treatment efficacy were retrospectively analyzed. Results The objective response rate was 51.7%, the disease control rate was 82.8%, and the median disease progression time was 3.2 months. The objective response rate, disease control rate and progression-free time of EGFR gene mutation positive patients were significantly better than that of EGFR Genotype wild-type patients; non-smoker objective response rate and disease progression-free time were significantly better than smokers; gender, clinical stage status and gefitinib efficacy was not significantly correlated. Conclusion Gefitinib treatment of advanced re-treatment of lung adenocarcinoma with significant efficacy, minor adverse reactions; EGFR gene mutation positive and non-smoking is a useful indicator of predicting the efficacy of gefitinib in the treatment of lung adenocarcinoma.